Related Experiment Video
Updated: Aug 14, 2026
06:18
Chimeric Antigen Receptor T Cell Manufacturing on an Automated Cell Processor
Published on: August 18, 2023
Mass Spectrometry in Allogeneic CAR-T Cell Manufacturing: From Cellular Starting Materials to Multi-Attribute Quality
Naryeong Kim1, Zhouyang Huang1, Michael Born2
1Cell Therapy Engineering and Development, Genentech South San Francisco, 1 DNA Way, South San Francisco, CA 94080, USA.
Cells
|August 13, 2026
Summary
Mass spectrometry (MS) enhances allogeneic CAR T-cell therapy manufacturing by providing comprehensive molecular analysis. This integration improves process understanding, quality control, and consistency for scalable cell therapies.
Area of Science:
- Biotechnology and Biomedical Engineering
- Immunotherapy and Cell Therapy
- Analytical Chemistry and Mass Spectrometry
Background:
- Chimeric antigen receptor (CAR) T-cell therapies show promise in blood cancers but face manufacturing challenges like complexity and variability, especially with autologous approaches.
- Allogeneic CAR T-cell therapies offer scalable, "off-the-shelf" production but introduce new hurdles in donor variability, genome editing, and product consistency.
- Current analytical methods (flow cytometry, ELISAs) are limited in capturing the full complexity of CAR T-cell products and are often used as isolated quality control measures.
Purpose of the Study:
- To review the applications and tools of mass spectrometry (MS) across the allogeneic CAR T-cell manufacturing workflow.
- To highlight how MS-driven analytics can address limitations in current CAR T-cell manufacturing.
- To demonstrate the potential of integrated MS analytics for improving process understanding, quality assessment, and regulatory decision-making in cell therapy development.
Main Methods:
- Examination of mass spectrometry (MS) applications throughout the allogeneic CAR T-cell workflow.
- Analysis of MS capabilities for characterizing gene-editing materials, in-process cultures, and final drug products.
- Review of MS for evaluating donor variability and post-infusion biomarkers.
Main Results:
- Mass spectrometry (MS) enables high-dimensional molecular characterization of gene-editing reagents, proteins, metabolites, and lipids.
- MS can analyze culture and spent-media composition throughout the CAR T-cell manufacturing process.
- MS provides a powerful platform for comprehensive quality assessment and process understanding in allogeneic CAR T-cell production.
Conclusions:
- Mass spectrometry (MS) is a crucial tool for overcoming current limitations in CAR T-cell manufacturing.
- Integrating MS into workflows enhances process understanding, quality control, and regulatory support.
- MS-driven analytics can facilitate the development of more consistent, scalable, and effective allogeneic CAR T-cell therapies.
